Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

Shigeo Shimose(Kurume University), Takuji Torimura(Omuta hospital), Masahito Nakano(Kurume University), Hironori Koga(Kurume University), Naoki Kamachi(Kurume University), Kazunori Noguchi(Omuta hospital), Hideya Suga(Yanagawa Rehabilitation Hospital), Masatoshi Tanaka(Fukushima Medical University), Hideki Iwamoto, Ryoko Kuromatsu(Kurume University), Takashi Niizeki(Kurume University), Takumi Kawaguchi(Kurume University), Taizo Yamaguchi, Yu Noda(Kurume University), Shusuke Okamura(Kurume University), Tomotake Shirono(Kurume University)
Cancers
July 11, 2020
10.3390/cancers12071867
Cited by 78

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504